Bioversys N
Clinical-stage biopharma developing antibacterial therapies for antimicrobial resistance.
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Manufacturing
Description
Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-26 07:00 |
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
|
English | 30.4 KB | ||
| 2025-03-26 01:00 |
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
|
English | 27.1 KB | ||
| 2025-03-26 00:00 |
BioVersys Annual Report 2024
|
English | 6.9 MB | ||
| 2025-03-20 07:00 |
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-…
|
English | 21.0 KB | ||
| 2025-03-19 07:00 |
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-…
|
English | 21.0 KB | ||
| 2025-03-14 07:00 |
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVE…
|
English | 6.1 KB | ||
| 2025-03-14 01:00 |
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVE…
|
English | 4.8 KB | ||
| 2025-03-11 07:00 |
Bioversys announces partial exercise of over-allotment option
|
English | 10.8 KB | ||
| 2025-03-10 07:00 |
Bioversys announces partial exercise of over-allotment option
|
English | 10.8 KB | ||
| 2025-03-10 01:00 |
Bioversys announces partial exercise of over-allotment option
|
English | 7.6 KB | ||
| 2025-03-01 00:00 |
Charter of the Audit and Risk Committee BioVersys AG
|
English | 396.2 KB | ||
| 2025-02-28 00:00 |
Charter of the Compensation and Nomination Committee BioVersys AG
|
English | 1018.7 KB | ||
| 2025-02-28 00:00 |
Disclosure, Reporting and Trading Policy BioVersys AG
|
English | 3.5 MB | ||
| 2025-02-28 00:00 |
Organizational Regulations of BioVersys AG
|
English | 1.2 MB | ||
| 2025-02-28 00:00 |
Charter of the Audit and Risk Committee BioVersys AG
|
English | 396.2 KB |
Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bioversys N
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bioversys N via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
